HiRO ANZ achieved rapid site activation and met the initial recruitment target of 450 participants within the 5-month period for a Phase 2 obesity clinical trial. Our collaboration with sites to initiate pre-screening and strategic planning allowed us to adapt quickly, even as the target increased to 495 participants over 7 months. Learn more about our recruitment strategies here: https://lnkd.in/gJZtUBP4 #ClinicalTrials #PatientRecruitment #HiROANZ #HealthcareInnovation
HiRO - Harvest Integrated Research Organization’s Post
More Relevant Posts
-
💡 Join Medpace for an Informative Webinar on Enhancing Obesity Clinical Trials! 🔍 Explore innovative strategies to improve obesity clinical trials, focusing on practical approaches to maximize #patientretention and protect endpoint integrity. The expert speakers will provide valuable insights into enhancing clinical trial outcomes through patient-centered methods and robust endpoint protection to ensure the reliability of results. ➡️ Learn more + register here: https://buff.ly/3Lwm96p #ClinicalTrials #Obesity #DrugDevelopment #ClinicalResearch #PatientCentricity #PatientRecruitment #ClinicalData #PatientCentric #PatientRetention
To view or add a comment, sign in
-
-
Register with the link below to hear my wife present on the topic of obesity.
The global #obesity epidemic continues to rise, presenting a serious public health challenge. Addressing obesity through the clinical trials of anti-obesity drugs requires innovative, patient-centered approaches. In an upcoming #webinar on August 22nd, Medpace advanced clinical practitioners and operational experts and will share insights into improving obesity clinical trial outcomes, with a focus on strategies to maximize patient retention and the importance of endpoint protection to ensure the integrity and reliability of the trial’s results. Register now to secure your spot: https://lnkd.in/gAx5JrFs
To view or add a comment, sign in
-
-
🎗️ World IBD Day | In this particular day, we are proud to share with you results from a survey about Preferences towards treatment attributes among patients with Crohn’s disease and UC, conducted by Takeda. The Poster was presented at the 19th Congress of the European Crohn’s and Colitis Organisation on 21–24 February 2024 in Stockholm. 📊 This study highlights the importance of treatment effectiveness, RoA and safety in patients with IBD. Personalised care is crucial given that preferences for treatment attributes may vary across countries and among patients. Discussions around shared decision-making regarding therapy choice and timing between patients and physicians are vital. We are proud to be able to contribute to the realization of complex DCE-type* studies all over the world (Taiwan, Saudi Arabia, Brazil, Argentina, Australia...). *What is a DCE, you ask? It's a powerful tool used to understand preferences and trade-offs by presenting individuals with alternative scenarios and asking them to choose their preferred option. At Carenity, we pride ourselves on being experts in this methodology, using it to delve deeper into understanding patient needs and desires. Take a look at the study results 👉 https://lnkd.in/e49TXTVN Congrats 🎉 to all the authors who worked on it: Marjorie Argollo, Yoon-Kyo An, Domingo Balderramo, Nahla Azzam, Chia-Jung Kuo, Olga F., Elenore Uy #PatientPreferences #DCE #HealthcareResearch #IBD
To view or add a comment, sign in
-
-
Enroll now for the Practical Strategies for Applying Evidence and Patient Perspectives to Improve Obesity Management program, hosted by Clinical Care Options and supported by Eli Lilly and Company! Expert faculty discuss strategies to improve the treatment of obesity, including reducing the risk of complications, individualizing treatment plans, and engaging patients in successful long-term weight loss. Learn more at https://bit.ly/3RtDVdW. #Obesity #ObesityTreatment #ObesityManagement
To view or add a comment, sign in
-
-
Clinical trials test potential treatments in human volunteers to see whether they should be approved for wider use in the general population, but many clinical trials for medications and devices exclude people with larger bodies. Excluding people with obesity and severe obesity is an example of explicit weight bias that can cause real harm. Obesity Action Coalition and other obesity advocates recently met with the Food and Drug Administration’s Commissioner Robert Califf to voice this concern. In our upcoming episode of Fresh Perspectives premiering in a week on August 30th, OAC President & CEO Joe Nadglowski and Vice President & Chief of Staff James Zervios discuss the details of the meeting, how OAC is fighting weight bias and what you can do to help make an impact for people with obesity. Read Why Aren’t Medications Fully Tested in People with Obesity? It’s Time to Raise Our Voices: https://lnkd.in/eexbfEQP
To view or add a comment, sign in
-
-
[SPUR applications] Improving patient retention in clinical trials isn’t a dream anymore. It’s a reality, thanks to SPUR’s objective and predictive behavioral data, integrated into our partner Clinical ink’s new platform GlucoseReady™. Dedicated to the transformation of cardiometabolic clinical trials (diabetes, obesity, NASH/MASH), GlucoseReady™ aims at enhancing patient outcomes through innovation and technology. Leveraged as a predictive behavioral assessment tool into the platform, SPUR™ behavioral data complements medical information to maintain patient engagement and minimize dropout rates. SPUR™ helps understand and mitigate factors leading to non-compliance, ensuring a smoother, more efficient trial process. How exciting to see our validated tool come to life for such ambitious goals! #ClinicalTrials #CardiometabolicDisease #SPUR #patientengagement
To view or add a comment, sign in
-
-
Executive Global Business Development Director - Head of Patient Centered Outcomes Research - RWE - Carenity at EvidentIQ Group | Patient Insights | Patient Centricity
A new patient preference study (DCE) in IBD. to learn more, PM me. Thanks Takeda for your trust. #PCOR #HEOR #PatientReportedOuctomes
🎗️ World IBD Day | In this particular day, we are proud to share with you results from a survey about Preferences towards treatment attributes among patients with Crohn’s disease and UC, conducted by Takeda. The Poster was presented at the 19th Congress of the European Crohn’s and Colitis Organisation on 21–24 February 2024 in Stockholm. 📊 This study highlights the importance of treatment effectiveness, RoA and safety in patients with IBD. Personalised care is crucial given that preferences for treatment attributes may vary across countries and among patients. Discussions around shared decision-making regarding therapy choice and timing between patients and physicians are vital. We are proud to be able to contribute to the realization of complex DCE-type* studies all over the world (Taiwan, Saudi Arabia, Brazil, Argentina, Australia...). *What is a DCE, you ask? It's a powerful tool used to understand preferences and trade-offs by presenting individuals with alternative scenarios and asking them to choose their preferred option. At Carenity, we pride ourselves on being experts in this methodology, using it to delve deeper into understanding patient needs and desires. Take a look at the study results 👉 https://lnkd.in/e49TXTVN Congrats 🎉 to all the authors who worked on it: Marjorie Argollo, Yoon-Kyo An, Domingo Balderramo, Nahla Azzam, Chia-Jung Kuo, Olga F., Elenore Uy #PatientPreferences #DCE #HealthcareResearch #IBD
To view or add a comment, sign in
-
-
Precision Health | Leadership | Stakeholder Engagement | Strategy & Business Development | Champion for Change | Views, opinions and posts are all my own, and do not represent any organisation, group or other individual.
#Pharmacogenomics (#PGx) plays an important role in identifying responders and non-responders to avoid specific adverse events and optimize drug dose in certain situations. Globally, the importance of PGx to drive personalised medicine is recognized in many disease areas – oncology, cardiac health, pain management, infectious disease and mental health. However, despite the mounting evidence of clinical & economic impact, many barriers still exist for the implementation and uptake of PGx as standard of care in Australia. 💊 Hosted by Thermo Fisher Scientific, and in partnership with Australian clinicians & experts in the field, this online webinar will showcase real-world evidence from Australian studies and the clinical utility of pharmacogenomics in #painmanagement #mentalhealth and #depression. 📅 Wednesday 18th October 2023 🕓 2 PM AEDT (60 mins) 💻 Register below ⬇ 🗣 A/Prof Leslie Sheffield and Tara Smith from myDNA 🗣 A/Prof Kathy Wu, St Vincent’s Health Network Sydney #personalisedmedicine #realworldevidence #genetictesting #clinicalgenomics #healthcare #ADRs #thermofisheremp
To view or add a comment, sign in
-
Director, Government Relations & Corporate Communications, Australia and New Zealand at Thermo Fisher Scientific
If you can, I recommend registering for this 60-minute insight into the real-world impact of pharmacogenomics on personalised medicine. #personalisedmedicine #realworldevidence #genetictesting #clinicalgenomics #healthcare #ADRs #thermofisheremp
Precision Health | Leadership | Stakeholder Engagement | Strategy & Business Development | Champion for Change | Views, opinions and posts are all my own, and do not represent any organisation, group or other individual.
#Pharmacogenomics (#PGx) plays an important role in identifying responders and non-responders to avoid specific adverse events and optimize drug dose in certain situations. Globally, the importance of PGx to drive personalised medicine is recognized in many disease areas – oncology, cardiac health, pain management, infectious disease and mental health. However, despite the mounting evidence of clinical & economic impact, many barriers still exist for the implementation and uptake of PGx as standard of care in Australia. 💊 Hosted by Thermo Fisher Scientific, and in partnership with Australian clinicians & experts in the field, this online webinar will showcase real-world evidence from Australian studies and the clinical utility of pharmacogenomics in #painmanagement #mentalhealth and #depression. 📅 Wednesday 18th October 2023 🕓 2 PM AEDT (60 mins) 💻 Register below ⬇ 🗣 A/Prof Leslie Sheffield and Tara Smith from myDNA 🗣 A/Prof Kathy Wu, St Vincent’s Health Network Sydney #personalisedmedicine #realworldevidence #genetictesting #clinicalgenomics #healthcare #ADRs #thermofisheremp
Pharmacogenomics Testing Webinar
To view or add a comment, sign in
-
DIVERSITY NEEDS TO THINK BIGGER As the FDA promotes its revised draft guidance on diversity in clinical trials, Industry must strive to also include obese patients in clinical trial populations. Excluding people with obesity from clinical trials has major safety profile implications for all populations. #clinicaltrials #diversity #access #obesity #transparency #dataintegrity #FDA
Obese People Are Missing in Many Clinical Trials, Increasing Their Health Risks
healthcentral.com
To view or add a comment, sign in
More from this author
-
Strategies for Enhancing the Diversity of Clinical Trial Populations
HiRO - Harvest Integrated Research Organization 1mo -
HiRO – Our Global Advantage, Tailored Solutions and Key Partnerships
HiRO - Harvest Integrated Research Organization 1mo -
HiRO – An Emerging Full-service Global CRO
HiRO - Harvest Integrated Research Organization 2mo